FY21 DOD Autism Research Program, Clinical Translational Research Award | W81XWH 21 ARP CTRA

Opportunity Information: Apply for W81XWH 21 ARP CTRA

The FY21 DOD Autism Research Program (ARP) Clinical Translational Research Award is a Department of Defense funding opportunity focused on moving autism spectrum disorder (ASD) research toward practical clinical impact. The intent is to fund early-stage, proof-of-principle translational studies that test hypothesis-driven and genuinely innovative interventions or clinical research approaches. In plain terms, the program is looking for projects that are ready to take a solid scientific idea and evaluate it in a way that could realistically lead to better care for people with ASD, especially by addressing gaps or shortcomings in current clinical options.

A central emphasis of this award is clinical relevance and near-term translational potential. Proposed studies should be designed to examine interventions or clinically oriented strategies with the potential to improve real-world deficits associated with ASD. Applicants are strongly encouraged to align their proposals with one of the FY21 ARP Clinical Translational Research Award Areas of Interest. If a project does not fit within those specified areas, the application is expected to make a clear case that it addresses a different but still critical ASD problem or unmet need. This framing signals that the program is open to novel ideas, but only when they are well-justified and clearly tied to meaningful outcomes for individuals with ASD.

The award is positioned as a stepping-stone toward larger clinical testing. The expected outcome from funded work is not necessarily a definitive, practice-changing trial right away, but rather high-quality preliminary evidence that can provide a strong scientific rationale for subsequent, larger-scale efficacy trials. The program is essentially supporting the earlier clinical translational phase where an intervention shows enough promise, feasibility, and signal of benefit to justify the time and expense of more definitive clinical trials. Ultimately, the long-term goal is to help drive development of interventions that could transform ASD clinical care, which means projects should be structured to produce interpretable, decision-ready results that inform what should be tested next and how.

From an administrative and funding standpoint, this opportunity is offered by the Department of Defense, Department of the Army, through USAMRAA, and it falls under CFDA number 12.420, which corresponds to military medical research and development activities. The funding instruments available include both grants and cooperative agreements, indicating that some awards may involve a more collaborative, actively managed relationship with the sponsor compared to a traditional grant. Eligibility is described as unrestricted, meaning it is broadly open to many entity types, with the caveat that applicants should still check any additional eligibility clarifications in the full announcement.

Key logistics included a posting/creation date of March 19, 2021, with an original application deadline of August 5, 2021. The opportunity anticipated making about two awards. The listed award ceiling is shown as 0, which typically suggests that the cap was not specified in that summary field or was defined elsewhere in the full funding announcement rather than in the brief record. Overall, the opportunity is best understood as a competitive, high-impact translational research mechanism aimed at generating early clinical evidence for promising ASD interventions, with a strong preference for projects that map onto stated program priorities and that can credibly support progression to later-stage clinical trials.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "FY21 DOD Autism Research Program, Clinical Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 19, 2021.
• Applicants must submit their applications by Aug 05, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 ARP CTRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: